Deepak Nitrite Fuels DCTL Growth with ₹135 Crore Capital Injection

CHEMICALS
Whalesbook Corporate News Logo
AuthorIshaan Verma|Published at:
Deepak Nitrite Fuels DCTL Growth with ₹135 Crore Capital Injection
Overview

Deepak Nitrite Limited and its subsidiary Deepak Phenolics Limited have jointly invested ₹135 crore into their wholly-owned subsidiary, Deepak Chem Tech Limited (DCTL). This capital injection is intended to strengthen DCTL for project execution and general corporate needs. The investment follows DCTL's notable turnover growth, projected at ₹9.43 crore for FY25, up from ₹0.86 crore in FY24.

Deepak Nitrite Limited, alongside its wholly-owned subsidiary Deepak Phenolics Limited, has collectively infused ₹135 crore into another subsidiary, Deepak Chem Tech Limited (DCTL).

The investment was made through the issuance of 9% convertible preference shares.

Deepak Phenolics Limited contributed ₹110 crore, and Deepak Nitrite invested ₹25 crore. Both transactions were at a par value of ₹100 per share.

This capital infusion is intended to strengthen DCTL's financial position, supporting its ongoing project expenses and general corporate needs.

Significance of the Funding

This significant capital injection aims to strengthen DCTL's balance sheet. The funding is crucial as DCTL undertakes major project developments in the chemical sector.

It demonstrates the parent companies' commitment to accelerating DCTL's growth by providing the financial backing for its ambitious plans and operations.

DCTL's Role and Ambitions

Deepak Chem Tech Limited (DCTL) is central to Deepak Nitrite's expansion into new chemical areas and projects. DCTL is involved in critical areas such as Nitric Acid production, fluorination, nitration, and hydrogenation.

DCTL is also pursuing major initiatives like a ₹5,000 crore Polycarbonate project and has a broader capex strategy aligned with Deepak Nitrite's overall investment plans, which involve significant outlays, potentially reaching up to ₹14,000 crore over several years.

Impact of the Infusion

  • Strengthened Financial Position: DCTL secures a stronger financial foundation, boosting its capacity for large-scale projects.
  • Project Acceleration: The funding should accelerate the progress of DCTL's ongoing and planned projects.
  • Parental Support: This shows continued strategic support from Deepak Nitrite and Deepak Phenolics for DCTL's growth plans.
  • Operational Flexibility: The funds offer flexibility for general corporate needs, supporting daily operations and strategic decisions.

Key Risks

DCTL's turnover has been historically low, at ₹0.86 crore in FY23-24, with a projected increase to ₹9.43 crore in FY24-25. This suggests that while growth is evident, the company is in the early stages of its large projects. Its financial performance will depend on project development and market acceptance.

Competitive Landscape

Deepak Nitrite operates in a competitive chemical market. Key peers in the Indian chemical sector include Tata Chemicals, Aarti Industries, and Navin Fluorine International.

While Tata Chemicals and Aarti Industries offer diversified chemical portfolios, Navin Fluorine is a direct competitor in specialty fluorochemicals, a segment DCTL is also building capabilities in.

Through subsidiaries like DCTL, Deepak Nitrite aims to build leadership in emerging chemical areas, mirroring expansion strategies seen among its peers.

What to Watch For

  • How DCTL deploys the ₹135 crore for project expenses and corporate needs.
  • Progress and commissioning timelines for DCTL's projects, including polycarbonate resins, nitric acid, and fluorination.
  • Sustained growth in DCTL's turnover and its contribution to Deepak Nitrite's overall financials.
  • Further announcements on DCTL's capacity expansions and market entry strategies in new chemical sectors.
Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.